Xeris Biopharma Holdings (XERS) Net Cash Flow (QoQ) (2021 - 2026)
Xeris Biopharma Holdings (XERS) Net Cash Flow (QoQ) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.24 Bn | 87.37 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.17 Bn | 1.97 Bn |
| 3 | Zoetis | 32.61 Bn | 30.67 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.28 Bn | 21.13 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 20.54 Bn | 20.54 Bn | - |
| 7 | Viatris | 20.31 Bn | 18.50 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.55 Bn | 12.12 Bn | 785.00 Mn |
| 10 | Xeris Biopharma Holdings | 1.42 Bn | 1.31 Bn | 72.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -96.36% |
| Dec 31, 2025 | -39.64% |
| Sep 30, 2025 | 3,711.95% |
| Jun 30, 2025 | 106.41% |
| Mar 31, 2025 | -206.39% |
| Dec 31, 2024 | 711.86% |
| Sep 30, 2024 | 130.00% |
| Jun 30, 2024 | -6.87% |
| Mar 31, 2024 | -122.55% |
| Dec 31, 2023 | 78,266.67% |
| Sep 30, 2023 | 99.43% |
| Jun 30, 2023 | 93.33% |
| Mar 31, 2023 | -268.18% |
| Dec 31, 2022 | 475.76% |
| Sep 30, 2022 | -33.22% |
| Jun 30, 2022 | -123.10% |
| Mar 31, 2022 | 369.10% |
| Dec 31, 2021 | 289.55% |
| Sep 30, 2021 | -36.56% |
| Jun 30, 2021 | -110.36% |